Immunotherapy is the only breakthrough therapy in cancer treatment in recent years. The goal of cancer immunotherapy is the generation of an effective anti-tumor T cell population.
One such approach involves adoptive transfer of T cells engineered with T cell receptor (TCR) genes, which has proven its feasibility and therapeutic potential in the treatment of various tumors. This form of T cell therapy includes: (1) isolation of T cells from patients; (2) genetic modification of patients’ T cells with tumor-specific TCR genes; and (3) reinfusion of modified T cells back to patients. It is envisioned as a reagent to confer tumor reactivity to patients who are lack of this immunity.
AgainChance is exploring novel T cell therapies based on two platforms-TCR technology and gamma-delta T cells. Our goal is to provide TCR-redirected T cell therapy in the off-the-shelf format.
